Reports cash, cash equivalents and marketable securities were $356.6M as of December 31. Subsequent to December 31 we raised $48.4M in net proceeds through our "At-the-market" program. We believe our current cash, cash equivalents and marketable securities are sufficient to fund our planned operations into 2025.."I am proud of our team’s exceptional performance in 2022 as we continued to build an amazing team, strengthen our financial position and successfully advance our portfolio of wholly-owned, internally-discovered small molecules targeting large immunology markets with high unmet medical need," said Raju Mohan, Chief Executive Officer. "We look forward to a potentially breakthrough year in 2023, with multiple key clinical milestones, including topline Phase 2 data for VTX002 in ulcerative colitis expected in H2 2023 and topline Phase 2 data for VTX958 in plaque psoriasis expected in Q4 2023. Additionally, we recently initiated a Phase 2 proof-of-mechanism trial of VTX2735 in CAPS patients, and we look forward to initiating a Phase 1 trial of our novel CNS-penetrant NRLP3 inhibitor VTX3232 in the first half of 2023."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTYX:
- Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
- Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
- Wells starts Ventyx at Overweight, sees multiple catalysts in next 12-18 months
- Ventyx Biosciences initiated with an Overweight at Wells Fargo
- Ventyx Biosciences price target raised to $65 from $60 at Oppenheimer
